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Abstract
Background: Brief Admission is a crisis and risk management strategy in which self-harming and suicidal
individuals with three or more diagnostic criteria of borderline personality disorder self-admit to hospital at times of
increasing risk when other efforts to stay safe are failing. Standardized in the current randomized controlled trial,
the intensity of Brief Admission Skåne is implemented in durations of three days, with a maximum frequency of
three times a month. Brief Admission is integrated into existing treatment plans in advance of crises to prevent
reliance on general psychiatric admissions for risk management, as these may be lengthy, unstructured, and of
uncertain therapeutic value.
Methods/design: The overall objective of the Brief Admission Skåne randomized controlled trial is to determine if
Brief Admission can replace general psychiatric admission for self-harming and suicidal individuals with complex
mental illness at times of escalating risk. Other objectives of the study are to evaluate whether Brief Admission
increases daily functioning and enhances coping, reduces psychiatric symptoms including frequency and severity of
self-harm and suicidal behaviours. A final objective is to determine if Brief Admission is an effective crisis
management model for this population. Participants are randomized at an individual level to either Brief Admission
Skåne plus Treatment as Usual or Treatment As Usual. Based on a priori power analyses, N = 124 participants will be
recruited to the study. Data collection is in progress, and will continue until June 2018. All participant data are
single-blinded and will be handled with intention-to-treat analysis.
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Discussion: Based on the combined clinical experience of our international research group, the Brief Admission
Skåne randomized controlled trial upon which the current protocol is based represents the first initiative to
standardize, implement and evaluate Brief Admission amongst self-harming and suicidal individuals, including those
with borderline traits. Objectively measuring protocol fidelity and developing English-language Brief Admission
study protocols and training materials are implementation and dissemination targets developed in order to
facilitate adherent international export of Brief Admission Skåne.
Trial registration: NCT02985047. Registered November 25, 2016. Retrospectively registered.
Keywords: Brief admission Skåne, Self-harm, Suicide, Borderline personality disorder, BASRCT
Background
As stated by the National Institute for Health and Care
Excellence [1] “The experience of care for people who
self-harm is often unacceptable.” There is a misconcep-
tion even amongst some health care providers that indi-
viduals who self-harm are choosing their suffering. This
creates stigma regarding self-harm, about which individ-
uals with lived experience are often well aware. Similar
experiences with respect to stigma have been reported
by people diagnosed with borderline personality disorder
(BPD [2]). General psychiatric admission (GPA) is of
uncertain therapeutic value amongst self-harming and
suicidal individuals, and potentially harmful if lengthy
and unstructured for those with BPD [3–5]. Specialized
evidence-based services developed for these individuals at
times they cannot keep themselves safe is often needed,
but more often lacking. These services are particularly
necessary in situations of unique vulnerability, such as
suicidal crises. When suicide and severe self-harm are
acute risks it is essential that services are offered in a com-
passionate manner that honours the human dignity of the
person who is suffering [6, 7].
A report commissioned by Sweden’s National Self-harm
Project examined the prevalence of self-harm among indi-
viduals receiving mental health services across 84 psychi-
atric settings from 15 cities [8]. The sample was comprised
of participants aged 12 years and older. Results indicated
that almost half of the participants currently receiving
mental health services had self-harmed during the past
6 months, with one in six adults self-harming five or more
times the last 6 months. Three out of four young women
between the ages of 12 and 18 reported self-harming over
the same time period. Of those who had engaged in self-
harming behaviour, more than half had attempted suicide
at least once during their lifetime [8]. For a sub-group of
individuals, often with BPD, self-harming behaviours are
frequent and risk for suicide is recurrent [9].
Over the last 20 years several psychotherapeutic inter-
ventions have evolved for the treatment of individuals
with self-harm as well as BPD [3, 5, 10, 11]. However,
during crises and associated increases in self-harm and
suicidal ideation, recommendations for clinical care are
still conflicting. For individuals with imminent suicidal
ideation, without recurrent self-harm, the routine prac-
tice is to offer psychiatric admission to an inpatient unit
[12]. For individuals with recurrent suicidal ideation and
self-harm, often diagnosed with BPD, the risk for iatro-
genic effects may be considerable. Lengthy hospital ad-
missions without a clear treatment structure are
associated with clinical and functional decompensation
amongst this group [3–5]. Consequentially there is a
clinical practice of avoiding inpatient admission of indi-
viduals with these presenting features. The absence of
consensus amongst crisis management recommenda-
tions is a regular burden requiring strategic planning at
junctures that would be better suited to the provision of
seamless clinical care. Ideally, the situation would not re-
quire having to re-negotiate the entire process (to admit
or not admit) on behalf of every acutely suicidal individual
when they themselves feel out of control.
What is BA?
The nature of the BA admission is goal-driven struc-
tured respite. A BA admission is not a stand-alone
clinical intervention, nor is it unstructured rest. Rather,
BA serves as a method of providing structured support
to address the stress that is generating self-harming or
suicidal escalation. The conditions, parameters and goals
for adding BA to a treatment plan are negotiated with
the individual and their care providers in advance of
crises, effectively “striking while the iron is cold.” The
aim in doing so is to support the individual’s autonomy in
creating and maintaining control over their health care
and their situation more generally, and to avoid power-
struggles and decompensation when it is time to leave the
BA. The negotiation process results in a contract describ-
ing how BA should be implemented for the individual
based on their individual needs and preferences.
Over repeated experiences of BA, the structure and
stabilizing aspects of BA generalizes to the individuals’
life outside of the hospital, leading to reduced reliance
on acute and general psychiatric hospital admissions
while remaining safe in times of crisis [13, 14]. By learn-
ing new ways of responding/not responding during
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crises, and staying safe regardless of current emotion,
gains from psychotherapy engaged in concurrently with
BA (treatment as usual: TAU) facilitates capability to
manage subsequent crises without turning to self-harm
and suicidal behaviour [15]. For individuals with BPD,
BA can be offered concurrently with treatments such as
Dialectical Behavior Therapy (DBT) or Mentalization-
Based Therapy (MBT). In fact, adding BA to an existing
treatment plan may enable those with BPD to remain in
specialized evidence-based treatments delivered on an
outpatient basis. Careful consideration, planning and
support are part of developing the BA contract so that
those participating are helped to continue to engage in
important activities outside the hospital during BA. An
example is continuing to attend DBT skills training
groups during BA if the individual is already committed
to that treatment on an outpatient basis.
Brief Admission in the Netherlands
In the Netherlands, BA was initially developed [16] to
manage the vulnerability of some individuals with complex
mental illness towards frequent crises including escalation
of suicidality. The purpose of BA was crisis management in
general, and avoidance of lengthy inpatient admissions in
particular. As a crisis management strategy, BA was rapidly
adopted across most mental health service centers in the
Netherlands. Helleman, Goossens, Kaasenbrood, and van
Achterberg [13] conducted a phenomenological study
involving 17 participants with lived experience of BA in
the Netherlands. With respect to the key features of BA
that were identified, participants endorsed: (i) the
organization of the brief admission; (ii) the quality of the
contact with a nurse over the course of BA; (iii) the
restorative value of time out from daily life; and (iv) the ex-
perienced value of the intervention. Participants described
appreciating how BA prevented the onset and escalation of
self-harm and suicide attempts at times of high stress and
distress. The nature of self-admission to BA was de-
scribed as key to providing support at the exact time
needed by participants. A key feature of BA is partici-
pant control over when the BA occurs, as well as its
duration within the confines of short parameters, such
as days [13]. Twenty years after its inception in the
Netherlands, the Dutch Multidisciplinary Guidelines
for Personality Disorders [17] recommended BA as a
crisis management strategy for individuals with a BPD.
Review of research on brief admission for crisis
management of self-harming, suicidal, and borderline
individuals
The majority of the literature on Brief Admission (BA) is
concerned with short-term hospitalization of individuals
in the acute stages of mental health crises related to
substance and alcohol use disorders, psychosis or
neurological events and the inpatient management of
their sequelae. Aside from the Dutch literature summa-
rized above, only two publications [18, 19] were identi-
fied as related to brief admission for self-harming,
suicidal, and borderline individuals. These contributions
to the literature and their similarities and differences to
Brief Admission Skåne (BAS) are summarized as follows.
Siefert’s [18] Goal-Oriented Limited-Duration BPD
Inpatient Treatment (GOLDBIT) is similar to BAS in
that both are time-limited adjunctive initiatives rather than
stand-alone therapeutic interventions/clinical therapies.
Rather, GOLDBIT and BAS are intended to support
longer-term outpatient clinical interventions, such as Dia-
lectical Behavior Therapy (DBT) or Mentalization-Based
Therapy (MBT). A planned short inpatient stay to regain
structure and return to ongoing outpatient therapy is
viewed by both Siefert [18] and our group as more desir-
able than losing membership in specialized longer-term
outpatient therapy due to unplanned prolonged emergency
psychiatric admission. Like BAS, in GOLDBIT an assess-
ment of feasibility is conducted prior to determining
whether it is an appropriate add-on to existing care. Also
similar to BAS, GOLDBIT has “meta-goals,” such as ar-
ticulating expectations, creating structure, and engagement
with staff and life on the unit, with an aim of generalizing
the of benefits of GOLDBIT to life outside of the admis-
sion [18]. Finally, both BAS and GOLDBIT have clear, pre-
determined discharge dates, planned in advance to avoid
power-struggles and decompensation at termination. A
short admission in GOLDBIT is longer in duration than
BAS (10 days compared to 3 days in BAS). A difference
between GOLDBIT and BAS is that BAS is available for all
self-harming and suicidal individuals, not those specifically
diagnosed with borderline personality disorder (BPD) as in
GOLDBIT.
The second publication relevant to BAS focused on
the management of BPD [19], which is in alignment with
the views and purpose of BAS except the broader inclu-
sion of self-harming individuals into BAS both with and
without BPD diagnoses. These authors noted that spe-
cialized, evidence-based treatments for BPD are prefera-
ble to lengthy or unstructured hospital stays or general
treatment as usual. Where emergency admissions are in-
volved to de-escalate suicidality, their recommendations
were to keep admissions as short as possible, to reduce
loss of stabilizing aspects of life such as employment,
social contacts, and housing. Biskin and Paris also noted
iatrogenic effects of lengthy and unstructured inpatient
admissions as risk-factors for BPD individuals. There
was no mention of the role of standardized brief admis-
sion, possibly because the place of publication was
Canada, where brief admission is not a current feature
of the mental health system. Nevertheless, theirs is an
important paper both in acknowledging expert opinion
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that BPD be treated primarily on an outpatient basis1
(with the exception of specialized residential treatments,
such as those pioneered by Bohus et al. [20–22]). As
well, they generated recommendations for admissions
that are consistent with BAS, specifically that admissions
be: 1. Brief in nature; 2. Not intended to replace psycho-
therapy; 3. Used to manage suicidal crisis in the short term,
and 4. Ideally a component of the best treatment for this
population, which is specialized, evidence-based psycho-
therapy delivered on an outpatient basis with the exception
of aforementioned specialized residential treatments. All of
these features are consistent with BAS.
Brief Admission (BA) is a crisis management strategy
that enables individuals to admit themselves to hospital
without prior physician consultation at times when there
is risk for increasing self-harm, escalating suicidality, and
when efforts to stay safe are failing. The person seeking
BA can decide for themselves when they need hospital
admission to prevent decompensation of mental health
functioning, for a short period (days) at a maximum
frequency (admissions per month). The model has been
used in the Netherlands for more than 30 years but has
not yet been standardized or scientifically evaluated by
randomized controlled trial. The Brief Admission Skåne
(BAS) RCT upon which the current protocol is based
contributes this data to the literature.
Participants in the BASRCT are randomized to receive
either BA alongside their regular mental health services/
treatment as usual (BAS + TAU) or treatment as usual
(TAU). These comparators were selected to determine
whether BA added to an existing treatment plan can
reduce the number of days spent in general psychiatric
admission and associated forced care incidents amongst
a population who tend to be heavy consumers of mental
health services. These comparators further allow the
evaluation of whether, as in the Netherlands, access to
BA alongside TAU is associated with more positive ex-
perience of mental health services, increased autonomy,
and increased quality of life.
BAS objectives
The primary aim of the BASRCT is to determine if BA
can replace general psychiatric admissions (GPA) for
individuals with complex mental illness with recent
histories of self-harm, at acute risk for escalating self-
harm or suicide. This will be determined by examining
hospital data collected from clinical records pertaining
to:
i. Number of days with BA admission
ii. Number of days with GPA to hospital
iii. Number of days admitted under forced (involuntary)
psychiatric admission
iv. Frequency of involuntary care incidents (e.g.
restraints, seclusion and involuntary medication)
The secondary aims of the BAS study are to determine
whether BA can:
i. Increase the individual’s level of functioning in
activities of daily life
ii. Increase the individual’s ability to cope effectively
with life stress
iii. Reduce the individual’s global psychiatric symptoms
iv. Reduce the frequency of all self-harming behaviours
including suicide attempts
v. Reduce the severity of self-harming behaviours;
vi. Serve as feasible risk and crisis management model
in the care of self-harming individuals, who may also
be at risk for suicide.
The measures used over the course of the RCT to
address these research objectives and their associated
outcomes are listed in Table 1.
Trial design
The BASRCT design is an interventional parallel random-
ized controlled trial with single-blinding. Participants are
randomized at an individual level to either BAS + TAU or
TAU. All participants are randomized one-to one (1:1).
Methods: participants, interventions, and outcomes
Study setting
Psykiatri Skåne is the provincial public mental health
organization in the region of Skåne, South Sweden, pro-
viding individuals living in Skåne with psychiatric care.
Region Skåne has approximately 1.3 million inhabitants
and is served by four geographically organized adult psy-
chiatric clinics. The geographically based organizations
are served by one inpatient psychiatric hospital, and
several outpatient clinics. Every inpatient setting has two
to four wards treating individuals in the acute stages of
primarily non-psychotic mental illnesses.
For the purpose of testing the effectiveness of Brief
Admission Skåne (BAS) in the current RCT, a general
psychiatric ward was chosen in each participating site by
their management team comprised by clinical director,
the psychiatrist with ultimate clinical responsibility at
the unit and the heads of the local wards and units. To
avoid drift of the effects of BA with treatment as usual
(TAU), acute general psychiatric admission for partici-
pants included in the study was directed to units other
than those providing BA whenever possible.
Participants
Inclusion criteria:
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– Current episodes of self-harm and/or recurrent
suicidality
– Fulfilling at least three criteria for a diagnosis of
BPD.
– Admitted to psychiatric hospital for acute care for at
least seven days or presenting to the psychiatric
emergency department at least three times during
the last six months.
– Age 18–60 years.
Exclusion criteria:
– No regular contact with outpatient psychiatric
services.
– Unstable housing
– Somatic disorder or need for medication
management that significantly contributes to
inclusion criteria (e.g. if self-harm only occurs
during episodes of hypoglycemia in a diabetic person
or in someone with substance-induced psychosis).
BAS randomized controlled trial: intervention
Brief Admission Skåne (BAS) refers to the current
randomized controlled trial evaluating the effectiveness
of a standardized version of brief admission (BA) for
individuals with recurrent self-harm, escalating suicidal-
ity, and BPD. Within BAS, individuals can be admitted
to hospital for a maximum duration of three consecutive
days at a maximum frequency of three times per month.
BAS is defined by these parameters as well as by the
approach or demeanor of clinical staff, which should be
warm, welcoming and bright.
Participants randomized to TAU will receive no inter-
vention from the study protocol, except the baseline
assessments and repeated assessments administered on
the same schedule as described for the treatment group,
every six months. They will not be given the evaluation
measures that are specific to the BAS intervention (the
IES and the CES [23]).
A broad spectrum of mental health services is com-
prised by TAU. These include psychopharmacological
treatment and psychosocial interventions ranging
from regular supportive contact with an out-patient
clinician to time-specific specialized evidence-based
treatments such as DBT and MBT. Involuntary and
voluntary psychiatric admission (GPA) is used conser-
vatively, in situations with very high risk for severe
harm (for example, with a high probability of death)
of self or others, or for specific treatment of co-
morbid psychiatric disorders.
Table 1 Summary of the BAS Measures
Data provider Outcome variable Questionnaires
Hospital records N of days with general admission to hospital -
N of visits at the psychiatric emergency department -
N of days with involuntary admission to hospital as defined by LPT -
N of involuntary acts as defined by LPT (Act on compulsory
psychiatric care)
-
N of BAS -
N of days with BAS -
Research persons Self-harm Five Self-Harm Behaviour Groupings Measure (5S–HM [34])
Self-harm The Inventory of Statements About Self-Injury (ISAS [35])
Emotion regulation The Difficulties in Emotion Regulation Scale (DERS [36])
Coping strategies The Brief COPE [37]
Health and disability The World Health Organization Disability Assessment Schedule II
(WHODAS 2.0 [38])
Developmental cognitive disabilities
Alcohol consumption, and alcohol-related problems.
Five questions [39]
The Alcohol Use Disorder Identification Test (AUDIT [40])
Drug abuse and drug-related problems. The Drug Use Disorders Identification Test (DUDIT [41])
Client satisfaction with human services The Client Satisfaction Questionnaire (CSQ [42])
Client satisfaction with BAS Individual’s Experience Scale (IES [23])
Clinicians Clinician, administering BAS, satisfaction with BAS Clinician’s Experience Scale (CES [23])
Psychiatrists Psychiatric disorders The Mini-International Neuropsychiatric Interview
(M.I.N.I. 6.0 [43])
Personality disorders Structured Clinical Interview for DSM IV Axis II disorders
(SCID II [44])
The severity of the patient’s illness Clinical Global Impression Severity (CGI-S [45])
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Criteria for discontinuing or modifying allocated
interventions for a given participant
Controlled by the participant: The participant modifies
the dose by choosing the duration and frequency of the
BAs that they will add to their treatment plan, within
the parameters of BAS (maximum three day admissions,
up to three times a month.) If a participant tries BA and
does not find it to be helpful, meaningful or if the par-
ticipant finds BA harmful, they can choose to not initiate
further BAs. If during a BA a participant wishes to
terminate prior to the duration they planned in advance,
the goal of the BA is reviewed, and the individual is
asked to decide whether their desire to leave early is in
the service of that goal. If a BA is terminated early, the
outcome is evaluated afterwards with the individual and
their care providers.
Controlled by the clinician: A BA is terminated follow-
ing severe self-harm during BA, escalating suicidality
during BA, or on occasions in which the participant has
broken the terms of the contract signed prior to their
first BA (for a sample contract please see [23]). If an
adverse event involves clinical worsening with respect to
self-harm or suicidality, the person is walked over to the
Emergency Room and admitted as a general psychiatric
inpatient. Care is taken to communicate the fact that a
BA terminated early is a learning opportunity rather than
a failure. The individual is warmly welcome back to the
ward for another BA when they are ready to try again.
Controlled by the clinician in collaboration with the PI
and the research team: If a participant engages in severe
self-harm during BA, attempts suicide, or in situations
in which other people at the ward were put at risk
(adverse events), the BAS contract is put on hold until
the individual can learn and express what skills they can
use to avoid these outcomes in the future.
Strategies to improve adherence and fidelity
The National Institutes of Health Behavior Change
Consortium (BCC) define treatment fidelity as methods
and measures used over the course of implementation
of an intervention to increase validity and reliability
[24]. To monitor and ensure that BA “dose” content,
and conditions were as adherent to the formulation of
BA as possible, an objectively scored fidelity measure
was developed [23]. The Brief Admission Skåne Fidelity
Measure (BASFM) has accompanying rating forms to
evaluate every fifth BAS negotiation2 that is videotaped
for this purpose. Videotaped contract negotiations are
then dubbed from Swedish into English for fidelity rat-
ing. M. Helleman and S. Liljedahl independently rate
each videotaped negotiation, compare fidelity ratings,
resolve any discrepancies in ratings between them, and
give feedback to the principal investigator (S. Westling)
who shares feedback directly with clinical staff
delivering BAS. Where deviations to adherence are sig-
nificant, emergency feedback is given at the earliest
convenience of all parties. Inter-rater reliability of fidel-
ity ratings will be calculated alongside the results of the
BASRCT.
Further based upon the BCC treatment fidelity recom-
mendations, parallel user experience measures were devel-
oped, for administration both to individuals receiving BA
and to clinicians providing BA [23] within BAS. These
measures are administered to individuals and their BA
clinicians on every occasion that BA was delivered, as well
as after every negotiation (every 6 months). Results of
these measures were calculated at the conclusion of the
pilot phase of BAS implementation. Both individual and
clinician experience measures, as well as the procedure of
data collection was streamlined to better reflect clinical
reality on the wards as explained by clinical staff and indi-
viduals with lived experience receiving BA.
Outcomes
For a list of all primary and secondary outcomes includ-
ing specific measurement variables, please see Table 2:
All items from the World Health Organization Trial
Registration Data Set.
Participant timeline
All participating staff at inpatient and outpatient units
were given the inclusion and exclusion criteria for BAS
and were instructed to ask prospective BAS candidates
fulfilling these if they would like to participate in the
BASRCT. If a prospective participant was interested,
contact was made with the principal investigator (PI) of
the study who requested consent to participate in BAS
and conducted a psychiatric assessment to verify if inclu-
sion criteria were fulfilled. A time schedule of enrolment,
interventions, and assessments are presented in Fig. 1. A
list of abbreviations is in Additional file 1: Appendix 1.
Sample size
Data collection is in progress, until the conclusion of the
trial (June 2018). The online program G*Power, 3. 1. 7
[25] was used to calculate a priori power for analyzing
main effects and interactions for an A X B mixed design
where A is a between-subject factor with two levels
(experimental and control groups) and B is a within-
subjects factor with three levels (three repeated assess-
ments). Assuming that three effects (i.e., between levels
of the factor A, within levels of the factor B and within-
between interaction A X B), are of medium size
(f = 0.25; see [26]), a significance level is of α = .05, and
the power values of the F tests are.85, a total of N = 98
must be recruited. Attrition in this population based on
previous studies has been estimated to be approximately
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Table 2 All items from the World Health Organization Trial Registration Data Set in relation to the Brief Admission Skåne
Randomized Controlled Trial (BASRCT)
Data category Information
Primary registry and trial identifying number Clinicaltrials.gov NCT02985047
Date of registration in primary registry November 25, 2016
Secondary identifying numbers N/A
Sources(s) of monetary or material support Mats Paulsson Stiftelse; Swedish Research Council; Sweden’s National Self-Harm
Project (NSP); Regional Research Funds; Söderström-Königska Foundation; Ellen
och Henrik Sjöbrings Minnesfond; OM Persson Stiftelse; Maggie Stephens Stiftelse
Primary Sponsor Region Skåne
Clinical Psychiatric Research Center
Baravägen 1
22,185 Lund
Sweden
Secondary Sponsor None
Contact for public queries Sophie Liljedahl
Department of Psychology
Lund University
Box 213 221 85, Lund
Sweden
Phone: +46 0708 88 5618
Email: sophie.liljedahl@psy.lu.se
Contact for scientific queries Sophie Liljedahl (contact information above)
Sophie Westling, M. D., Ph. D.
Lund University
Box 213 221 85, Lund
Sweden
Phone:+46 0735 62 6099
Email: sophie.westling@med.lu.se
Public Title Brief Admission Skåne (BAS)
Brukarstyrd Inläggning (BI) – Swedish
Scientific Title Brief Admission Skåne Randomised Controlled Trial (BASRCT)
Countries of recruitment Sweden
Health condition or problem(s) studied Individuals with three or more symptoms of borderline personality disorder; self-harming
and/or suicidal individuals receiving public mental health services in the region of Skåne
(South Sweden).
Intervention(s) Brief Admission + Treatment As Usual OR Treatment As Ususal (BA + TAU OR TAU)
Key inclusion and exclusion criteria Ages eligible: ≥ 18 years to 60 years.
Sexes eligible: Individuals or any sex or gender
Accepts healthy volunteers: no
Inclusion criteria: adult patient (≥ 18 years to age 60), individuals receiving public mental
health services in the region of Skåne, currently engages in self-harm and/or recurrent
suicidal behavior, fulfills at least three criteria for a diagnosis of BPD, admitted to psychiatric
hospital for acute care for at least 7 days or presenting to the psychiatric emergency
department at least 3 times during the last 6 months.
Exclusion criteria: No regular contact with outpatient psychiatric services, unstable housing,
somatic disorder that significantly contributes to inclusion criteria
Study type Interventional
Allocation: randomized
Masked: single blind
Primary purpose: self-harm and suicide crisis and risk management
Date of first enrolment October 2015
Target sample size 124
Recruitment status Recruiting
Primary outcome(s) 1. Number of days with hospital admission
Time frame: Change between the period from 12 months retrospectively to baseline and
the period from
baseline to 12 months prospectively.
2. Number of days with Brief Admission, general psychiatric admission, forced (involuntary)
admission
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25% [11, 27]. In order to attain the required sample size
for these power estimate, including expected attrition, a
total of N = 124 participants is required.
Recruitment
The first three months of the study (Oct, 2015–Jan, 2016)
served as a pilot phase with the goal of optimizing the
intervention, evaluating the inclusion and exclusion
criteria and preliminary testing to determine whether the
quality and quantity of assessments were adequate and
feasible. The experience of receiving and delivering BA
was evaluated with IES [23] and CES [23], respectively.
Data collection was suspended from January to March,
2016. During this phase every videotaped negotiation
was translated and evaluated by the authors of the Brief
Admission Skåne Fidelity Measure (BASFM [23]). Feed-
back from the evaluation measures (the IES and CES
[23]) was extracted and reviewed by the senior re-
searchers in this study to determine whether the content
or procedures are functioning as anticipated, and to
determine whether there are any areas in need of
improvement. Substantial changes to any aspect of the
study or its measures were sent to the Regional Ethics
board (EPN Lund) for review. All requested changes
(listed below) were formally approved:
 The contract was revised after feedback from
participants and clinicians.
 Minor linguistic changes were made in the IES and
CES after feedback from clinicians and participants.
 The procedure administering the IES and CES was
revised in order to facilitate prompt evaluation.
 The BASFM [23] was revised over the course of the
pilot phase. The most significant change was to
evaluate only what could be objectively rated by
video-tape, which was the negotiation process.
Other changes occurred with phrasing and scoring
of BASFM, to reduce cultural differences between
interpretations of clinician warmth, and to give
partial scores for items on the BASFM where
some component of the item was present but
other required components were missing.
Data collection for the active phase of the study began
in March 2016 (baseline) and will terminate in June 2018.
Methods: assignment of interventions
Allocation
Randomization and sequence generation
Ethical approval for this study was received in 2014
(Dnr2014/570, Lund). In the current RCT (Brief Ad-
mission Skåne: BAS) participants are randomized at
an individual level to either BA plus Treatment as
Usual (TAU). Block randomization, using tables with
random numbers with blocks of four are used in order to
minimize the confounding effect of changes in general
Table 2 All items from the World Health Organization Trial Registration Data Set in relation to the Brief Admission Skåne
Randomized Controlled Trial (BASRCT) (Continued)
Secondary outcome(s) 1. Frequency of forced acts (e.g. restraints and forced medication).
Time frame: Change between the period from 12 month retrospectively to Baseline and
the period from baseline to 12 months prospectively.
2. Individuals’ Experiences of the intervention. Time frame: Data collected at each Brief
Admission during a period of 140 weeks.
Outcome: Scores from the questionnaires developed for the method: Individual’s Experience Scale (IES).
3. Clinicians’ experiences of the intervention. Time frame: Data collected at each Brief Admission
during a period of 140 weeks.
Outcome: Scores from the questionnaires developed for the method: Clinician’s Experience Scale (CES)
4. Frequency of all self-harming behaviours including suicide attempts.
Time frame: Change in frequency between baseline, 6 months and 12 months prospectively.
Outcome: Scores from the Five Self-Harm Behaviour Groupings Measure (5S–HM)
5. Severity of self-harming behaviours
Time frame: Change in severity between baseline, 6 months and 12 months prospectively.
Outcome: Scores from the Five Self-Harm Behaviour Groupings Measure (5S–HM)
6. Level of functioning in activities of daily life.
Time frame: Change in ratings between baseline, 6 months and 12 months prospectively.
Outcome: Scores from the World Health Organization Disability Assessment Schedule II (WHODAS 2.0)
7. Ability to cope effectively with life stress.
Time frame: Change in ratings between baseline, 6 months and 12 months prospectively.
Outcome: Scores from The Brief COPE
8. Ability to regulate emotions
Time frame: Change in ratings between baseline, 6 months and 12 months prospectively.
Outcome: Scores on the Difficulties in Emotion Regulation Scale (DERS)
9. Global psychiatric symptoms.
Time frame: Change in ratings between baseline, 6 months and 12 months prospectively.
Outcome: Scores from the Clinical Global Impression Severity Scale (CGISS)
10. Satisfaction with health care
Time frame: Change in ratings between baseline, 6 months and 12 months prospectively.
Outcome: Scores on the Client Satisfaction Questionnaire (CSQ)
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care over time. Randomization is stratified according to
treatment site. Random number tables are generated using
the web-based tool Research Randomizer [28]. The data
will be handled with Intention To Treat (ITT) analysis, so
that once participants are randomized, their data will be
included in all analyses regardless of whether they drop
out of the study prior to its termination. Data from all
interview and self-report measures are collected in an
encrypted online data management program housed at a
local Swedish university.
For each participant in the BASRCT, hospital data are
collected retrospectively from 12 months prior to base-
line, over the course of the active phase of the study,
and at six and 12 months post-baseline. Since access to
BA requires a BA contract that is negotiated during a
relatively stable phase involving the BA recipient as
well as the outpatient clinician and a clinician from the
BA unit, a delay can be expected between
randomization and access to the intervention. In order
to monitor the intervention group only when having
access to BA, baseline for individuals randomized to
the BA condition was set to the date that the BA con-
tract was introduced and signed by the participant. For
individuals randomized to the control condition, base-
line was set to the date that screening assessment and
randomization occurred.
Sequence allocation, implementation and blinding
The third author of this paper (D. D.) generated the
allocation sequence, which was handled by a research
nurse who prepared and sealed four series of consecu-
tively numbered, sealed, opaque randomization
Fig. 1 SPIRIT flow diagram: Schedule of enrolment, interventions and assessments
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envelopes. Numbers were generated one per site and
strata, each envelope containing treatment instruc-
tions, as well as information on the procedures of data
collection during the study. The PI (SW) enrolled the
participants giving each of them a consecutive re-
search number also generated one per site and strata.
If the participant was eligible for the study SW assigned
them by giving them a consecutive randomization enve-
lope which was opened and signed by the participant. As
the investigator was blind to the allocation, this study is a
single blind trial.
Methods: assignment of interventions
Data collection methods
A complete description of assessment data and collection
of outcome, baseline, and other trial data is summarized
in Table 2: All items from the World Health Organization
Trial Registration Data Set. The timeline of assessments is
included in Fig. 1. SPIRIT flow diagram of enrolment, in-
terventions and assessment. The BASFM, described above
in the section on Strategies to improve adherence and fi-
delity has been published as component of the BASP [23].
Processes to promote data quality: BAS training
A standardized 1-day workshop was developed to train
clinical staff on the intervention and documentation
encompassed by BAS, as well as a 1.5 h lecture for man-
agers, physicians and administrators. This step was taken
to follow fidelity recommendations from Bellg et al. [24]
in relation to standardizing provider training, measuring
provider skill acquisition post-training, and following up
on how provider skills are retained over time. Accord-
ingly, all staff at hospital wards where BA was going to
be delivered received the 1-day workshop. Additional
60–90 min information on the BASRCT was offered to
all staff working with self-harming, suicidal, and border-
line individuals at the emergency wards, other inpatient
wards, outpatient units, as well as a team of temporary
relief staff. Outpatient clinicians working with the target
group as well as relief staff were also encouraged to
attend the 1-day workshop. The 1-day workshop was
evaluated by attendees at the conclusion of each work-
shop. At every clinic a single information session for ad-
ministrators and physicians was offered alongside two
options to receive the 1-day workshops on how to
deliver BAS to clinical staff. Newly employed staff and
those involved in delivering BAS but having missed the
BAS training were offered to attend workshops at other
sites. After all sites had participated in the workshops
and information sessions, new workshops and informa-
tion sessions were offered every 6 months to ensure
newly recruited staff were adequately trained in adminis-
tering BAS. Information on how the BASRCT has pro-
gressed is shared with administrators and physicians in
the form of yearly lectures. While BAS is ongoing,
monthly consultation is offered to all staff working at
wards where BA is being offered as part of the BASRCT.
On-call supervision is also available for more urgent
situations.
Data management
Interview data will be coded by trained research staff
and entered into statistical packages for future analyses.
Since data is not entered manually we will not employ
the procedure of data double-entry. Encrypted data col-
lection measures are generated from a data management
system at Lund University created for this purpose
(Sunet Survey).3 BASRCT data will be downloaded from
Sunet Survey, saved on encrypted memory drives and
stored in a locked cabinet in accordance with ethical
guidelines for data management set by the regional
ethical review board (EPN: Lund.)
Statistical methods
All statistical analyses will be conducted on the full
intent-to-treat sample and will be based on change in
mean scale scores between baseline and 6- and 12-
month post-assessments. For a complete list of primary
and secondary outcomes, see Table 1.
Mixed-effect regression models with random slopes and
intercepts will be used to test whether the change on out-
come variables over time will be more pronounced for
BAS + TAU group compared to the TAU-WL group
(group × time interaction). Besides the interaction term, all
models will also include the main effects of time (in weeks)
and group. Socio-demographic variables found to differ be-
tween treatment and control groups at baseline or that
predict change in outcome will be included in statistical
analyses as covariates.
In order to the address potential effects of missing
data, we will apply a pattern-mixture approach described
by Hedeker and Gibbons [29] to test whether the
addition of (1) the completer status, (2) the completer
status × time interaction, and (3) the 3-way interaction
between completer status, time and group would signifi-
cantly contribute to the core model.
Effect sizes will be calculated both for those patients
who completed the study and for the intention-to-treat
population.
Methods: monitoring
Data monitoring
There are no competing interests associated with this
study from either the authors or the sponsor. Because all
data are monitored by the research group, a data monitor-
ing committee is not needed. The PI reports all activities
and significant deviations from the original protocol to
the VKP (Region Skåne), the Swedish Research Council,
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Mats Paulssons stiftelse and the National Self-Harm pro-
ject every six months, alongside national trainings presen-
tations and international presentations describing BAS.
Interim analyses were conducted after the pilot phase of
the study was complete. No further interim analyses were
conducted and none are planned. The BASRCT will be
terminated upon the full recruitment of N = 124 partici-
pants, based on a priori power analyses. Stopping guide-
lines are increasing self-harm, escalating suicidality and
posing risk of harm to others on the ward amongst more
than three individuals in the BAS + TAU condition.
Harms
All adverse and unintended events are directly reported
from the ward staff to the PI and recorded in a log for
adverse and unintended events. Isolated acts of minor
self-harm were handled within the BA parameters
(conversation with the ward clinician at discharge and at
the start of next admission about precipitating factors,
analysis of the event, and discussion of how to prevent
further acts of self-harm going forward). Severe self-
harm or putting others on the ward at risk was handled
by putting a hold on the BA contract. While the contract
was on hold the individual was encouraged to learn new
skills to prevent further adverse events during future BAs.
As soon as the individual and the outpatient clinician had
agreed that this was achieved, the contract was updated at
which time the individual explained how the newly
learned skills could help them avoid future self-
harming behaviours, or avoid placing others in the
ward at risk.
Auditing
The PI and/or a trained research assistant visited all
wards participating in the study on a monthly basis,
speaking with ward staff regarding the procedures, offer-
ing consultation, giving feedback on adherence, as well
as feedback regarding any contact with an individual
receiving BA during the past month. This process was
not independent from the BASRCT researchers, but it
was independent from the VKP/Region Skåne.
Protocol amendments
All aspects of the BASRCT protocol are published in
Additional file 2: Appendix 3 of a manual developed
from the BASRCT, including a theoretical background,
training materials, measures developed for the BASRCT
and the BASFM [23]. The protocol is updated alongside
ethically approved changes to the BASRCT, which is
further updated on a quarterly basis in the trial registry
at ClinicalTrials.gov. The protocol version upon which
this paper is based is Liljedahl, Helleman, Daukantaitė,
and Westling [23].
Consent and confidentiality
The procedures for obtaining consent from potential
BASRCT participants are as follows:
1. Individuals with a clinical presentation suggesting
that they may fulfill inclusion criteria are asked by
their outpatient clinician, a clinician at the
psychiatric emergency unit or a clinician working at
one of the inpatient wards if they want to participate
in the study. If the individual is interested in
participating, the clinician shares contact
information to the BASRCT PI or RA.
2. The PI or RA provides written and verbal information
about the study, including time for questions to the
prospective participant. The information is given
either in person (if the prospective participant is on a
ward) or on the telephone and by mail (if the
prospective participant is at home).
3. If the prospective participant is still interested, the
PI or RA schedules an appointment.
4. At this appointment, the PI offers to give verbal
information again and actively asks if the prospective
participant has new questions since the last contact
regarding the BASRCT. After this the prospective
participant is asked to sign the consent form
(please see Additional file 2: Appendix 3), which
is co-signed by the PI obtaining consent.
Part of the approved ethical application includes an
Information Letter (Additional file 2: Appendix 3a) to pro-
spective participants, describing all aspects of the BASRCT,
including the intention to publish de-identified aggregate
data both in press and at national and international scien-
tific meetings and conferences. Consent forms are signed to
indicate understanding of, and agreement with the right to
confidentiality, safe storage of de-identified records that are
confidentially shredded 10 years after study completion, de-
tails of participation in the trial, the ability to change ones’
mind about all aspects of study participation and adherence
to data privacy laws. Informed consent authorized by a
signed consent form (Additional file 2: Appendix 3b) is part
of the process of becoming eligible to participate in the
BASRCT.
In 2016 the PI of the BASRCT applied for and received
an ethical amendment to our original approved applica-
tion (Dnr2014/570, Lund) to recruit participants from
the existing study to participate in a 5 year follow-up
analysis of biomarkers. A separate consent procedure
was developed for this ancillary study (described in the
Information Letter in Additional file 2: Appendix 3c).
Declaration of interests
The authors declare that they have no financial or other
competing interests.
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Access to data
The authors of this paper are the members of the re-
search team. They will all have access to a de-identified
final trial dataset for publications completed by this re-
search group. The datasets generated and/or analysed
during the current study are not publicly available due
to the fact that they contain personal health information,
and are protected by laws that govern protection of
personal health information. All data requests to the
corresponding author would first be discussed amongst
the research group and then vetted by the Chair of the
Regional Ethics Board (EPN: Lund, Sweden).
Ancillary and post-trial care
Participants are not paid for participating in the project,
nor do they have arrangements for post-trial care or
insurance since the intervention BA is being offered in
addition to their general mental health services/treat-
ment as usual, and is not associated with any risks.
Dissemination policy
Key functions of dissemination and implementation re-
search are increasing the likelihood that evidence-based in-
terventions are taken up in practice and administered with
fidelity [30]. The purpose of Brief Admission Skåne (BAS) is
to contribute a first step in establishing effectiveness of BA
+ TAU over TAU through the current BASRCT. We are
mindful that subsequent research evaluating this method is
required prior to its designation as an evidence-based prac-
tice [31–33]. Nevertheless, we wanted to follow best prac-
tices for enhancing treatment fidelity as a step towards
feasible implementation and dissemination, both within the
trial and going forward after its termination.
We are an international research group, facing the
aforementioned problems of clinical management of
crises related to escalating self-harm and suicide in indi-
viduals with and without borderline personality disorder.
Clinical management of these crises is problematic in
every one of our home countries with the exception of
the Netherlands, where crises are curtailed by BA, which
is a feature of the Dutch mental health system. Accord-
ingly, we were mindful of the vitality of implementation
and dissemination especially for international export
from the early planning stages of BAS.
Our in-person observation of BA in the Netherlands
generated the hypothesis that the clinical approach or “de-
meanour” of staff providing BA is key to its popularity
amongst people receiving mental health services as well as
its broad implementation in the Netherlands. Given that
“clinical demeanour” is a challenging construct to
operationalize, and that it can be easily interpreted sub-
jectively, our focus was on measuring fidelity from before
the BASRCT began. For this reason, the best practices
and recommendations from the National Institutes of
Health and Behaviour Change Consortium (BCC [24])
guidance were followed as closely as possible for enhan-
cing treatment fidelity in the BASRCT. If our primary hy-
potheses are supported, that is, if BAS can replace general
psychiatric admissions for individuals with self-harm at
acute risk for suicide, our efforts in implementation and
dissemination will continue with an aim for BAS to
be merited as a recognized evidence-based interven-
tion. To facilitate international export, English lan-
guage Train-the-Trainer manuals are being developed,
and the BAS fidelity measure and the BAS protocol
including clinician training materials have published
towards this purpose [23].
Roles and responsibilities and authorship eligibility
1. SW is the PI of the study and has been involved
in all aspects of study development and
implementation. She is the principal and in some
cases sole recipient of funding for the RCT and
she is primarily responsible for data acquisition,
training and supervision of clinicians and
administrators participating in the RCT. She
contributed to the BASRCT protocol.
2. SL contributed to the conception of the study, was
involved in drafting the manuscript and revising it
critically for important intellectual content; she
principally developed the fidelity measure and
BASRCT manual, protocol, and fidelity measure, and
will train others in coding BAS fidelity. She
contributed to all aspects of study development and
principally developed the manuscript and its
revisions.
3. MH contributed to the conception of the study and
co-developed the fidelity measure and manual. She
contributes to training and supervision of clinicians
and administrators participating in the RCT and has
contributed original content to the manuscript and
its revisions. She contributed to the BASRCT
protocol.
4. DD made essential contributions to conception and
study design and is responsible for data analysis and
interpretation of data and writing results. She
contributed original content to the manuscript and
its revisions. She contributed to the BASRCT
protocol.
5. ÅW agreed to be accountable for all aspects of the
work in ensuring that questions related to the
accuracy or integrity of any part of the work are
appropriately investigated and resolved.
All authors read and approved the final manuscript.
No professional writers were used.
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Discussion
Brief Admission (BA) is an adjunctive treatment in
which individuals can engage alongside specialized
evidence-based psychotherapy offered on an outpatient
basis. As a concurrent structured respite plan, BA has
been well received by individuals and care providers for
more than 20 years in the Netherlands [17] as a crisis
management approach for individuals with a BPD. The
Brief Admission Skåne (BAS) randomized controlled
trial upon which the current protocol is based represents
the first international effort to standardize, export, and
implement BA into a different language, cultural setting,
and country from which it was developed.
Implementing BA in a general psychiatric setting is
an extensive and time-consuming process. All staff
and management at the participating psychiatric
wards, emergency departments and outpatient units
must be informed of the availability of BA, be trained
in the referral process, and understand BA parameters
and implementation well enough to either explain it
adequately to prospective participants or deliver BA
themselves. Importantly, all professionals must also be
willing to initiate and maintain good collaboration
with the BA ward, the BAS PI and RA, and amongst
each other.
Implementing BA to a novel setting outside of its
country of origin has required regular information-
sharing, education and consultation to each entire set-
ting in which BAS has been implemented by a full-time
PI and a part-time RA. Daily communication between
the PI and RA and regular communication with the
wards involved in BAS implementation was required in
order to maintain adherent BA delivery, as well as to
promptly solve problems as they arose. Regular
(monthly, and if needed weekly) consultation as well as
repeated (at least 2 times a year) training on BAS has
been offered over the duration of the trial. Practical and
clinical emergencies related to suicidality or other crises
arising during BA were managed by direct clinical super-
vision with the PI, who is a psychiatrist, on an on-call
basis. In more complex clinical situations, urgent con-
sultation amongst the research team, the majority of
who are also clinicians, was required so that adherent
decisions could be made by consensus. Although BA it-
self is relatively simple compared to specialized
evidence-based treatments for this population, the co-
ordination and collaboration surrounding its adherent
implementation is resource and time-intensive. An es-
sential facilitating factor has been ongoing collegial and
healthy collaborations within the BASRCT, the vitality of
which cannot be overstated.
At the time of writing this paper no meta-analyses,
randomized controlled trials or controlled trials were
published testing the efficacy or effectiveness of BA as a
replacement for GPA amongst self-harming and suicidal
individuals with three or more criteria of borderline per-
sonality disorder. In this manner, the BASRCT upon
which the current protocol is based represents a unique
contribution to the literature. The current BASRCT is
the first step in the direction of generating data to deter-
mine its effectiveness.
Endnotes
1This was first attributed to Linehan [3]
2The negotiation process is a conversation that pre-
cedes entry into BA at which time every aspect of BA is
explained to prospective candidate, preferences are re-
corded, questions are answered, and BA contracts are
signed. The signed contract becomes part of the person’s
care plan and hospital record.
3For more information about Sunet Survey please see:
http://www.staff.lu.se/research-and-education/education-
support/quality-enhancement/sunet-survey-a-survey-
tool
4International exchange rates were calculated on
2017–04-22.
5Regionala etikprövningsnämnden i Lund Box, 133 221
00 Lund, Sweden
Additional files
Additional file 1: Appendix 1 - List of abbreviations. (DOCX 19 kb)
Additional file 2: Appendix 3 - Model consent forms and other related
documentation given to participants and authorized surrogates. Plans for
collection, laboratory evaluation, and storage of biological specimens for
genetic or molecular analysis in the current trial and for future use in
ancillary studies. (DOCX 29 kb)
Acknowledgements
The authors wish to thank Alva Bèrnér, Research Assistant/Psychologist under
Supervised Practice, and Johan Olsson, Research Nurse, for their assistance
with data collection and developing the RCT framework.
Funding
The project is fully externally financed with multi-year national funding in-
cluding proceeds from Vetenskapsrådet/The Swedish Research Council, a
grant that was won from the most prestigious and competitive granting
source in Sweden.
All funding over the course of the trial at the time of publication:
Mats Paulsson Stiftelse 3.000.000 SEK (3 years × 1.000.000 SEK)
Swedish Research Council 1.350.000 SEK (3 years × 450.000 SEK)
National Self-harm project 900.000 SEK (3 years × 300.000 SEK)
Regional Research Funds 360.000 SEK (2 years × 180.000 SEK)
Söderström-Königska Foundation 425.000 SEK (175.000 + 250.000 SEK)
Ellen och Henrik Sjöbrings Minnesfond 80.000 SEK (30.000 + 50.000 SEK)
OM Persson Stiftelse 50.000 SEK (30.000 + 20.000 SEK)
Maggie Stephens Stiftelse 10.000 SEK
TOTAL: 6.175.000 SEK
= 558.945 GBP
= 694.335 USD
= 908.983 CAD4
The funding bodies had no role or impact on the design of the study, data
collection, or in writing the manuscript. The sponsor with legal responsibility for
the research participants and study is Region Skåne. The PI worked with the
rest of the research team to plan, develop, and implement all aspects of the
Liljedahl et al. BMC Psychiatry  (2017) 17:220 Page 13 of 15
study. Accordingly, there is no steering committee, endpoint adjudication
committee, separate data management team, or other individuals overseeing
the trial. The coordinating centre is the Vetenskapcentrum, Psykiatri (VKP) in
Lund, with responsibility for the distribution of study funds.
Availability of data and materials
The datasets generated and/or analysed during the current study are not
publicly available due to the fact that they contain personal health
information, and are protected by laws that govern protection of personal
health information. All data requests to the corresponding author would first
be discussed amongst the research group and then vetted by the Chair of
the Regional Ethics Board (EPN: Lund, Sweden). All BASRCT materials
including the study protocol are available online for free access: http://
portal.research.lu.se/portal/files/24269973/Brief_Admission_Manual.pdf
Authors’ contributions
SW is the PI of the study and has been involved in all aspects of study
development and implementation. She is the principal and in some cases sole
recipient of funding for the RCT and she is primarily responsible for data
acquisition, training and supervision of clinicians and administrators
participating in the RCT. She contributed to the BASRCT protocol. SL
contributed to the conception of the study, was involved in drafting the
manuscript and revising it critically for important intellectual content; she
principally developed the fidelity measure and BASRCT manual, protocol, and
fidelity measure, and will train others in coding BAS fidelity. She contributed to
all aspects of study development and principally developed the manuscript and
its revisions. MH contributed to the conception of the study and co-developed
the fidelity measure and manual. She contributes to training and supervision of
clinicians and administrators participating in the RCT and has contributed
original content to the manuscript and its revisions. She contributed to the
BASRCT protocol. DD made essential contributions to conception and study
design and is responsible for data analysis and interpretation of data and
writing results. She contributed original content to the manuscript and its
revisions. She contributed to the BASRCT protocol. ÅW agreed to be accountable
for all aspects of the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and resolved. All
authors read and approved the final manuscript. No professional writers were
used.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All prospective participants receive an Information Letter (Additional file 2:
Appendix 3a), describing all aspects of the BASRCT, including the intention
to publish de-identified aggregate data both in press and at national and
international scientific meetings and conferences.
Ethics approval and consent to participate
Ethical approval to conduct the BASRCT was applied for and formally
approved on August 14, 2014 by the Regional ethics review board in Lund.5
The committee’s reference number that indicates approval of the specific
BASRCT is Dnr2014/570, Lund.
Author details
1Department of Psychology, Lund University, Box 213 SE-221 00 Lund,
Sweden. 2Department of Clinical Sciences, Lund, Psychiatry, Clinical
Psychiatric Research Center, Lund University, Lund, Region Skane, Sweden.
3Dimence Group, Centre for Mental Health Care, Burgemeester Roelenweg 9,
8021 EV Zwolle, the Netherlands.
Received: 26 March 2017 Accepted: 25 May 2017
References
1. NICE: Self-harm: Clinical guideline16. (2004). https://www.nice.org.uk/
guidance/qs34. Accessed 1 Sept 2016.
2. Horn N, Johnstone L, Brooke S. Some service user perspectives on the
diagnosis of borderline personality disorder. J Ment Health. 2007;16:255–69.
doi:10.1080/09638230601056371.
3. Linehan MM. Cognitive behavioral therapy of borderline personality
disorder. New York, NY: Guilford Press; 1993.
4. Lundh L-G: Behandlingseffekter på självskadebeteende:Vad visar
forskningen?. (2013). http://nationellasjalvskadeprojektet.se/wp-content/
uploads/2016/06/LundhForskningsöversiktbehandlingsjälvskadebeteende2.
pdf. Accessed 15 Feb 2017.
5. Lundh L-G. Behandling vid icke-suicidalt självskadebeteende kräver tydlig
struktur. Randomiserade kontrollerade studier visar evidens för DBT och
MBT. Läkartidiningen. 2014;111:CH9E.
6. NICE: QS34: Quality standard for self-harm. (2013). https://www.nice.org.uk/
guidance/qs34. Accessed 16 Feb 2017.
7. Westling S, Liljedahl S, Holmqvist-Larsson M, Parnén H, Zetterqvist M,
Ershammar D: Rekommendationer för insatser vid självskadebeteende. 2nd ed.
(2016). http://nationellasjalvskadeprojektet.se/wp-content/uploads/2015/12/
Rekommendationer-Självskadebeteende-rev-2016.pdf. Accessed 3 Nov 2016.
8. Odelius C, Ramklint M: En nationell kartläggnng av förekomsten av
självskadande beteende hos patienter inom barn & ungdoms- och
vuxenpsykiatrin. Nationella självskadeprojektet och Uppsala universitet.
(2014). http://nationellasjalvskadeprojektet.se/wp-content/uploads/2016/06/
Slutrapportprevalensmätning140410.pdf. Accessed 8 Sept 2016.
9. Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline
personality disorder. Lancet. 2004;364:453–61. doi:10.1016/S0140-
6736(04)16770-6.
10. Hawton K, Witt KG, Salisbury TL, Arensman E, Gunnell D, Hazell P, et al.
Psychosocial interventions following self-harm in adults: a systematic review and
meta-analysis. Lancet Psychiatry. 2016;3:740–50. doi:10.1016/S2215-0366(16)30070-0.
11. Stoffers JM, Vollm BA, Rucker G, Timmer A, Huband N, Lieb K: Psychological
therapies for people with borderline personality disorder. Cochrane
Database Syst Rev. 2012:CD005652. doi:10.1002/14651858.CD005652.pub2.
12. Salander-Renberg E, Sunnqvist C, Westrin Å, Waern M, Jokinen J, Runeson B.
Suicidnära patienter – kliniska riktlinjer för utredning och vård. Stockholm,
Sweden: Svenska Psykiatriska Föreningen och Gothia Fortbildning AB; 2013.
13. Helleman M, Goossens PJ, Kaasenbrood A, van Achterberg T. Experiences of
patients with borderline personality disorder with the brief admission
intervention: a phenomenological study. Int J Ment Health Nurs. 2014;23:
442–50. doi:10.1111/inm.12074.
14. Helleman M, Goossens PJ, Kaasenbrood A, van Achterberg T. Evidence base
and components of brief admission as an intervention for patients with
borderline personality disorder: a review of the literature. Perspect Psychiatr
Care. 2014;50:65–75. doi:10.1111/ppc.12023.
15. Helleman M, Goossens PJ, Kaasenbrood A, van Achterberg T. Brief
admissions during prolonged treatment in a case involving borderline
personality disorder and posttraumatic stress disorder: use and functions. J
Am Psychiatr Nurses Assoc. 2016;22:215–24. doi:10.1177/1078390316636196.
16. Van Veldhuizen JR, Wiersma D, Ram LM. Development of day treatment to
avoid admission. A message from the substitutionproject in drenthe
(Netherlands). Maandblad Geestelijke Volksgezondheid. 1988;43:1–13.
17. Dutch Psychiatric Multidisciplinary Guideline Committee. Dutch Multidisciplinary
Guidelines for Personality Disorders. Utrecht: Trimbos-institute; 2008.
18. Siefert CJ. A goal-oriented limited-duration approach for borderline
personality disorder during brief inpatient hospitalizations. Psychotherapy
(Chic). 2012;49:502–18. doi:10.1037/a0026128.
19. Biskin RS, Paris J. Management of borderline personality disorder. CMAJ.
2012;184:1897–902. doi:10.1503/cmaj.112055.
20. Bohus M, Dyer AS, Priebe K, Kruger A, Kleindienst N, Schmahl C, et al.
Dialectical behaviour therapy for post-traumatic stress disorder after
childhood sexual abuse in patients with and without borderline personality
disorder: a randomised controlled trial. Psychother Psychosom. 2013;82:221–
33. doi:10.1159/000348451.
21. Bohus M, Haaf B, Simms T, Limberger MF, Schmahl C, Unckel C, et al.
Effectiveness of inpatient dialectical behavioral therapy for borderline
personality disorder: a controlled trial. Behav res Ther. 2004;42:487–99. doi:
10.1016/S0005-7967(03)00174-8.
22. Bohus M, Haaf B, Stiglmayr C, Pohl U, Bohme R, Linehan M. Evaluation of
inpatient dialectical-behavioral therapy for borderline personality disorder-a
prospective study. Behav res Ther. 2000;38:875–87.
23. Liljedahl S, Helleman M, Daukantaite D, Westling S. Brief admission:
Manual for training and implementation developed from the Brief
Admission Skåne Randomized Controlled Trial (BASRCT). Training
Manual. Lund; 2017. http://portal.research.lu.se/portal/files/24269973/
Brief_Admission_Manual.pdf.
Liljedahl et al. BMC Psychiatry  (2017) 17:220 Page 14 of 15
24. Bellg AJ, Borrelli B, Resnick B, Hecht J, Minicucci DS, Ory M, et al. Enhancing
treatment fidelity in health behavior change studies: best practices and
recommendations from the nih behavior change consortium. Health
Psychol. 2004;23:443–51. doi:10.1037/0278-6133.23.5.443.
25. Faul F, Erdfelder E, Lang AG, Buchner A. G*power 3: a flexible statistical
power analysis program for the social, behavioral, and biomedical sciences.
Behav res Methods. 2007;39:175–91.
26. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed.
Hillsdale, N.J.: L. Erlbaum Associates; 1988.
27. Nadort M, Arntz A, Smit JH, Giesen-Bloo J, Eikelenboom M, Spinhoven
P, et al. Implementation of outpatient schema therapy for borderline
personality disorder: study design. BMC Psychiatry. 2009;9:64. doi:10.
1186/1471-244X-9-64.
28. Urbaniak GC, Plous S: Research randomizer (version 3.0) [computer
software]. (2015) http://www.randomizer.org/. Accessed 1 Feb 2017.
29. Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models
for missing data in longitudinal studies. Psychol Methods. 1997;2:64–78.
30. Tabak RG, Khoong EC, Chambers DA, Brownson RC. Bridging research and
practice: models for dissemination and implementation research. Am J Prev
med. 2012;43:337–50. doi:10.1016/j.amepre.2012.05.024.
31. APA presidential task force on evidence-based practice: Evidence-based practice
in psychology. Am Psych. 2006;61:271–85. doi:10.1037/0003-066X.61.4.271.
32. Chambless DL, Baker MJ, Baucom DH, Beutler L, Calhoun KS, Crits-Christoph P,
et al. Update on empirically validated therapies. Clin Psychol. 1998;51:3–16.
33. Tolin DF, McKay D, Forman EM, Klonsky ED, Thombs BD. Empirically
supported treatment: recommendations for a new model. Clin Psychol Sci
Pract. 2015;22:317–38. doi:10.1111/cpsp.12122.
34. Liljedahl S, Westling S: A unified theoretical framework for understanding
suicidal and self-harming behavior: Synthesis of diverging definitions and
perspectives. Presented at the 3rd International Conference on Borderline
Personality Disorder and Allied Disorders. Rome, Italy; 2014.
35. Glenn CR, Klonsky ED. One-year test-retest reliability of the inventory of
statements about self-injury (isas). Assessment. 2011;18:375–8. doi:10.1177/
1073191111411669.
36. Gratz KL, Roemer L. Multidimensional assessment of emotion regulation an
dysregulation: development, factor structure, and initial validation of the difficulties
in emotion regulation scale. J Psychopathol Behav Assess. 2004;26:41–54.
37. Carver CS. You want to measure coping but your protocol’s too long:
consider the brief COPE. Int J Behav Med. 1997;4:92–100. doi:10.1207/
s15327558ijbm0401_6.
38. WHO: World Health Organization Disability Assessment Schedule II
(WHODAS 2.0.). (2014) http://www.who.int/classifications/icf/whodasii/en/.
Accessed 22 Oct 2016.
39. Holmqvist M, Nylander L: Angående screening formuläret “5 frågor”.
Screening questionnaire. Lund; 2013. https://vardgivare.skane.se/
SysSiteAssets/3.-kompetens-och-utveckling/sakkunniggrupper/ako-skane/
vuxna-medutvecklingsstorning-och-autism-19-mars/information-om-
screeningformularet-5-fragor.
40. Babor TF, Biddle-Higgins JC, Saunders JB, Monteiro MG. AUDIT: the alcohol
use disorders identification test: guidelines for use in primary health care.
Geneva, Switzerland: World Health Organization; 2001.
41. Berman AH, Bergman H, Palmstierna T, Schlyter F. Evaluation of the drug
use disorders identification test (DUDIT) in criminal justice and
detoxification settings and in a swedish population sample. Eur Addict res.
2005;11:22–31. doi:10.1159/000081413.
42. Nguyen TD, Attkisson CC, Stegner BL. Assessment of patient satisfaction:
development and refinement of a service evaluation questionnaire. Eval
Program Plann. 1983;6:299–313.
43. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al.
The mini-international neuropsychiatric interview (M.I.N.I.): the development
and validation of a structured diagnostic psychiatric interview for DSM-IV
and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33. quiz 4-57
44. First M, Spitzer R, Gibbon M, Williams J. The structured clinical interview for
DSM-III-R personality disorders (SCID-II). Part I: description. J Personal Disord.
1995;9:83–91.
45. Guy W. Clinical global impression severity, early clinical drug evaluation unit
(ecdeu) assessment manual for psychopharmacology. Rockville (Maryland):
National Institute of Mental Health, US Department of Health, Education,
and Welfare; 1976.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Liljedahl et al. BMC Psychiatry  (2017) 17:220 Page 15 of 15
